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Abstract
The CCN family of proteins, especially its prominent member, the Connective tissue growth factor (CTGF/CCN2) has been
identified as a possible biomarker for the diagnosis of fibrotic diseases. As a downstream mediator of TGF-b1 signalling, it is
involved in tissue scarring, stimulates interstitial deposition of extracellular matrix proteins, and promotes proliferation of
several cell types. Another member of this family, the Nephroblastoma-Overexpressed protein (NOV/CCN3), has growth-
inhibiting properties. First reports further suggest that these two CCN family members act opposite to each other in
regulating extracellular matrix protein expression and reciprocally influence their own expression when over-expressed. We
have established stable HEK and Flp-In-293 clones as productive sources for recombinant human CCN2/CTGF. In addition,
we generated an adenoviral vector for recombinant expression of rat NOV and established protocols to purify large
quantities of these CCN proteins. The identity of purified human CCN2/CTGF and rat CCN3/NOV was proven by In-gel digest
followed by ESI-TOF/MS mass spectrometry. The biological activity of purified proteins was demonstrated using a Smad3-
sensitive reporter gene and BrdU proliferation assay in permanent cell line EANhy 926 cells. We further demonstrate for the
first time that both recombinant CCN proteins are N-glycosylated.
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Introduction
Fibrosis is characterised by the deposition of the extracellular
matrix (ECM) proteins including collagens, structural glycopro-
teins, sulphated proteoglycans and hyaluronan into the subendo-
thelial space of Disse [1]. The biomechanical and biochemical
rebuilding of the tissue is induced by several important fibrogenic
cytokines including transforming growth factor (TGF-b, platelet
derived growth factor-B and -D (PDGF-BB, PDGF-DD), insulin-
like growth factor-1 (IGF-1) and endothelin-1 (ET-1) [2]. TGF-b
assists the wound repair and ECM deposition through intracellular
Smad proteins that transfer signals from the cell membrane to the
nucleus [3] and is of fundamental importance for the development
of excess fibrous connective tissue [4]. In this process, the
Connective Tissue Growth Factor (CCN2/CTGF) appears as
the downstream modulator of TGF-bsignalling. In liver for
example, CCN2/CTGF expression is in vitro triggered in
hepatocytes, fibroblasts and other cell types after stimulation with
TGF-b [5,6]. In vivo it could be shown, that the expression of
CCN2/CTGF was persistent after TGF-b stimulation. It acts as a
cofactor with TGF-b to induce hepatic fibrogenesis but is not
considered to be a potent fibrogenic agent on its own [7].
However, one of its important functions is to stimulate the
expression of ECM and proliferation of connective tissue cells to
close wounds inside of internal organ and skin tissue [8–10].
CCN2/CTGF is one of the six members of the CCN protein
family. The name of the family is an acronym of the first three
identified members, namely CYR61 (CCN1), CTGF (CCN2) and
the Nephroblastoma-overexpressed gene (NOV, CCN3). The
other members are WISP1 (ELM1, CCN4), WISP2 (COP-1,
CCN5) and WISP3 (CCN6). The different CCN proteins have a
similar predicted secondary structure consisting of 5 individual
modular domains that includes an insulin-like growth factor
binding domain, a von Willebrand factor type C repeat, a
thrombospondin type 1 repeat and a carboxyl-terminal cysteine
knot [11,12]. Moreover, the CCN proteins show a high sequence
identity between species with a highly conserved intramolecular
network of cysteine residues [13]. They own a variety of biological
functions that is strongly dependent on their cellular microenvi-
ronment [14] and fine-tuned by the activity and interplay of the
individual structural domains [15].
CCN2/CTGF is a 38-kDa protein was originally identified as a
growth factor secreted by human vascular endothelial cells [16]
and defined as the chondrocyte-specific gene product [17,18]. It is
over-expressed in many fibrotic disorders including scleroderma,
kidney and liver fibrosis [19–21,12] and constitutive expression of
CCN2/CTGF in tissues is considered to indicative for patholog-
ical lesions [5]. CCN2/CTGF promotes endothelial proliferation,
migration, survival and adhesion in angiogenesis [22]. Further-
more, CCN2/CTGF acts as an immediate early gene that are
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roles in the control of cell proliferation [9]. The TGF-b
dependency of CCN2/CTGF is mainly controlled by sequence
elements within the promoter that include a Smad-binding site
and a defined TGF-b response element [20,23].
Another member of the CCN family is the CCN3/NOV
protein that under certain conditions counteracts CCN2/CTGF
functions [24,25]. CCN3/NOV was first identified in Myeloblas-
tosis-associated virus-1-induced avian nephroblastomas [26,27]. It
is over-expressed in a broad range of tumors including Wilm’s
tumor and is further associated with neovascularisation and
vascular injuries in which it promotes pro-angiogenic activities
through integrin receptors in vascular endothelial cells [28,29].
Some other studies have shown that CCN3/NOV inhibits glioma
cell and PDGF-dependent glomerular cell proliferation [30,31].
However, the molecular understanding of CCN2/CTGF and
CCN3/NOV is still at the beginning and several key questions are
still unanswered. In particular, data is missing that explains the
regulatory network in which CCN2/CTGF promotes TGF-b
action that is necessary to maximally induce certain genes
including collagen type I and a-smooth muscle actin. Moreover,
the mechanisms that are required for the reported Yin/Yang
regulation of CCN2/CTGF and CCN3/NOV are still an enigma.
Presently, the performance of studies addressing these mechanistic
issues are somewhat limited by the lack of larger quantities of
biological active of respective CCN proteins.
In the present study, we aimed to develop devices that allow the
production of biological active recombinant CCN2/CTGF and
CCN3/NOV. We report about the establishment of transgenic cell
lines that over-express human CCN2/CTGF and an adenoviral
expression vector for production of rat CCN3/NOV. We have
established protocols for purification of these two CCN, and
biochemically and biologically characterised the recombinant
proteins by mass spectrometry, tryptic in-gel-digests, and prolifer-
ation and gene reporter assays in EANhy 926 cells. Moreover, we
demonstrate for the first time that both CCN2/CTGF and CCN3/
NOV are N-glycosylated and that the predicted Yin/Yang activity
both CCN proteins can be demonstrated in EANhy 926 cells.
Materials and Methods
Reagents
Recombinant TGF-b1, PDGF and the goat anti-mouse CCN3/
NOV polyclonal antibody AF1976 were obtained from R&D
Systems(Wiesbaden-Nordenstadt,Germany).The goat anti-human
CCN2/CTGF polyclonal antibody L-20 (sc-14939) was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). 1-Step BrdU
ELISA was obtained from Roche Biosciences (Mannheim,
Germany). The (CAGA)12-MLP-Luc vector [32] was kindly
provided by Peter ten Dijke (Department of Molecular Cell Biology,
Leiden University Medical Center). All chromatography columns
(HiTrap
TM Heparin HP, HiLoad 16/60 Superdex) were obtained
from GE Healthcare Life Sciences (GE, Mu ¨nchen, Germany).
Cell lines and culture
Flp-In-293 cells were obtained from Invitrogen (Darmstadt,
Germany). Parental HEK cells and COS-7 were obtained from
the ATCC (Manassas, VA). EANhy 926 cells [33] were kindly
provided by Dr. Cora-Jean Edgell (Department of Pathology and
Laboratory Medicine, Carolina Cardiovascular Biology Center,
Chapel Hill, NC). All cell lines were cultured in Dulbecco’s
Modified Eagle’s medium (DMEM) (BioWhittaker, Verviers,
Belgium) supplemented with streptomycin (100 mg/ml), penicillin
(100 IU/ml), L-glutamine (4 mM) and 10% fetal calf serum (FCS,
v/v) at 37uC in a humidified atmosphere containing 5% (v/v)
CO2. All cell culture supplements were obtained from PAA
Laboratories (Pasching, Austria). The HEK or Flp-In-293 clones
expressing recombinant human CCN2/CTGF (rhCTGF) were
cultured in the same medium containing additional 150 mg/ml
Hygromycin B (Roth, Karlsruhe, Germany). All cells were
cultivated until they reached 70–80% confluence. For subcultiva-
tion, they were washed 3 times with 16phosphate-buffered saline
(PBS, pH 7.4) and incubated for 15 min with Accutase
TM (PAA),
and plated on new cell culture dishes. The EANhy 926 cells were
sub-cultivated by use of 26trypsin (PAA).
Transfection experiments
All transfections were done with the FuGENE 6 transfection
reagent (Roche) according to the manufacturer’s instructions.
Briefly, HEK cells were seeded at 2610
5 cells per 6-well plate
(Sarstedt, Nu ¨rnbrecht, Germany) and incubated overnight in
culture medium. The medium was renewed and cells were
cultured for another 2 h period prior transfection. Sixteen hours
later, the medium was changed and clones were selected with
indicated antibiotics.
Stable expression of human CCN2/CTGF in HEK cells and
in the Flp-In-293 systems
The full length human CCN2/CTGF cDNA sequence was
amplified from expression clone pCEP4-hCTGF [34] that was kindly
provided by W. Sebald (Department of Physiological Chemistry II,
Theodor-Boveri Institute for Life Sciences (Biocenter), University of
Wuerzburg, Germany) using primers hCTGFfor (59-GAA TTC
ATG ACC GCC GCC AGT ATG GG-39)a n dh C T G F r e v ( 5 9-CTC
GAG TGC CAT GTC TCC GTA CAT CT-39). The amplicon was
cloned into the pGEM
TM-Easycloning vector (Promega, Mannheim,
Germany). Subsequently, the cDNA was released by the NotI
endonuclease and subcloned into the multiple cloning site of vector
pcDNA5/FRT/TO (Invitrogen) designed for use with the Flp-In-
293 system that allows production of stable cell clones expressing the
gene/protein of interest. The correct orientation within vector
pcDNA5/FRT/TO-hCTGFwas verified by sequencing. This vector
system contains a Hygromycin B resistance gene cassette allowing
selection and maintenance of transgenic clones. For generation of
stable expression clones, cells (HEK293A or Flp-In-293) were seeded
on 6-well plates and transfected with pcDNA5/FRT/TO-hCTGF
alone (HEK293A) or pcDNA5/FRT/TO-hCTGF and pOG44
(Invitrogen) (Flp-In-293) containing the transferase/integrase gene.
Transfected cells were selected with increasing concentrations of
Hygromycin B ranging from 50–400 mg/ml and dying of untrans-
fected cells was visualized by light microscopy. The ideal concentra-
tion was determined to 150 to 200 mg/ml of Hygromycin B for both
cell lines. Individual cell clones were established by limiting dilution
(0.5 cells/well in a 96-well plate) and numbered consecutively (HEK
c l o n e s :1 / 1 ,1 / 2 ,1 / 3e t c . ;F l p - I n - 2 9 3c l o n e s :W B 1 ,W B 2 ,W B 3e t c . ) .
Expression and secretion of recombinant CCN2/CTGF was
analyzed in ELISA [35] and Western blot using the CCN2/
CTGF-specific antibody sc-14939 (Santa Cruz). Stable cell clones
were frozen at 280uC using standard cryoconservation protocols.
Five of 120 initial cell clones were further expanded for production of
recombinant CCN2/CTGF. The expression of recombinant
CCN2/CTGF in each of both systems (HEK, Flp-In-293) was
documented for over 100 passages.
Immunocytochemistry
HEK and Flp-In-293 cells were seeded on poly-L-lysine-coated
glass cover slips that were prepared following a standard protocol.
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incubated for further 24 hr. Then the cells were washed in PBS,
fixed in 4% (v/v) paraformaldehyde in 16 PBS (pH 7.4) for
10 min, and permealized for 2 min on ice in 0.1% (w/v) sodium
citrate and 0.1% (v/v) Triton X. Cells were blocked for 10 min at
RT in Biotin Blocking Reagent (X0590) obtained from DAKO
(Hamburg, Germany) following manufacturer’s instructions.
Unspecific binding sites were further blocked in 50% (v/v) FCS,
1% BSA (w/v), and 0.1% (v/v) fish gelatine in PBS (pH 7.4) for
1 h. Finally, the cells were incubated overnight at 4uC in a 1:300
dilution of the anti-human CCN2/CTGF antibody (sc-14939) in
PBS containing 1% (w/v) BSA. Cells were washed and incubated
with an anti-goat-biotinylated antibody (1:300, DAKO) for 1 h,
and further with a Streptavidin/FITC-conjugate for 30 min at
RT. The nuclei were stained with DAPI. As a control, the cells
were incubated with an unspecific immunoglobulin.
Western blot analysis
The cells were washed three times in PBS and lysed in 250 ml
RIPA buffer (50 mM Tris/HCl (pH 7.4), 1% (v/v) NP-40, 0.25%
(w/v) sodium deochycholate, 150 mM NaCl, 0.1% (w/v) SDS,
1 mM EDTA, 1 mM PMSF, 1 mM Na3VO4, and 1 mM NaF)
per well of the 6-well plate. The protein concentration was
measured using the Micro BCA protein assay (Pierce Thermo
Scientific, Bonn, Germany). Proteins were separated in Bis/Tris
4–12% SDS-PAGE (Invitrogen) in MES buffer and transferred to
nitrocellulose membranes (Schleicher & Schu ¨ll, Dassel, Germany).
For documentation of equal protein loading, the membranes were
stained with Ponceau S and blocked for 30 min in 5% non-fat
dried milk dissolved in TBST containing 10 mM Tris (pH 8.0),
150 mM NaCl, and 0.1% (v/v) Tween-20. The membranes were
incubated overnight with a goat-anti-CCN2/CTGF (sc-14939) at
4uC under permanent shaking. The membranes were rinsed three
times in TBST and incubated with a monoclonal donkey anti-
goat-HRP conjugate (sc-2056, Santa Cruz) at RT for 1 h and
signal detection was conducted by use of the SuperSignal West
Pico Chemiluminescent Substrate (Pierce).
Generation of adenoviral expression vector AdEasy-CMV-
rNOV
To subclone the coding region of rat CCN3/NOV, a PCR was
performed using plasmid clone IRAKp961P24175Q (ImaGENE,
Berlin, Germany) as a template and primers 59-(TTG TAG AAT
TCA GCA GGC AGA ACA TG)-39 and 59-(TTA CCG GTA
CAT TTC TCC TCT GCT)-3. The amplicon was first cloned
into pGEM-T-Easy. Subsequently, the NOV containing sequence
was released by EcoRI/AgeI and cloned into respective sites of
vector pcDNA3.1/V5-HisA. Thereafter, the CCN3/NOV ex-
pression cassette was cut out by digest with EcoRI and PmeI,
blunted by Klenow, and cloned into vector adenoviral shuttle
vector pShuttle-CMV (Stratagene, Agilent Technologies, Wald-
bronn, Germany). For generation of a recombinant adenoviral
plasmid, the resulting vector pShuttle-CMV-rNOV was linearized
by PmeI digest and cotransfected with adenoviral backbone vector
pAdEasy-1 (Stratagene) into electroporation competent BJ5183
bacteria. A recombinant vector pAdEasy-1-CMV-rNOV was
isolated, characterized by restriction digest and sequencing, and
transfected into 293A cells to prepare adenoviral particles using
standard transfection, amplification and purification techniques.
Purification of recombinant CCN2/CTGF
For production of recombinant human CTGF, transgenic cells
were seeded at 2610
6 cells/culture dish and cultivated in growth
medium for 24 h. The medium was replaced one day later with
medium without FCS and expression/secretion of CCN2/CTGF
was allowed for 48 h. For purification of CCN2/CTGF, we
followed a two-step protocol. In the first step (heparin affinity
chromatography), we took advantage of the ability of CCN2/
CTGF to bind to heparin. The enriched growth medium was
centrifuged for 20 min at 50006g and supernatant was filtered
(0.22 mm). Then the growth medium was equilibrated with 1/10
VT of 100 mM Tris/HCl (pH 7.0) and subjected with a syringe to
a HiTrap
TM HP Heparin column (5 ml) that was equilibrated with
25 ml of 10 mM Tris/HCl (pH 7.0). The column was then
washed with 25 ml 10 mM Tris/HCl (pH 7.0) and the recombi-
nant protein was stepwise eluted from the heparin matrix with
10 mM Tris/HCl (pH 7.0) containing increasing concentrations
of NaCl (25 ml 0.15 M NaCl; 15 ml 0.4 M NaCl; and 10 ml each
of 0.4 M, 0.6 M, 0.8 M, 1.0 M, 1.2 M and 4 M NaCl). The
purest CCN2/CTGF fraction was eluted at 0.7 M NaCl. The
content of each fraction was tested by Western blot or ELISA.
CTGF containing fractions were pooled and subjected to a second
cycle of heparin affinity chromatography. Then the 0.7 M NaCl
fraction of the second Heparin affinity chromatography was
applied to a Superdex Sepharose 16/60 size-exclusion chroma-
tography that was run on a FPLC chromatographic system from
GE Biosciences equipped with a P-900 photometer. Fractions of 3
ml were collected and tested for the content of recombinant
CCN2/CTGF by ELISA or Western Blot. The purity of protein
solution was evaluated by SDS-PAGE and Coomassie Brilliant
Blue staining. All buffers and solutions used during the purification
of rhCTGF was filtered (0.22 mm) filtrated and kept at 4uC.
Purification of recombinant CCN3/NOV
The purification of recombinant rat NOV was performed from
pooled supernatants of COS-7 cells that were infected with the
adenoviral vector Ad-CMV-NOV and later harbored in DMEM
without FCS 48 h. After centrifugation (20 min, 50006g) and
filtration (0.22 mm), the equilibrated supernatant (10 mM Tris,
pH 7.0) was subjected to heparin affinity chromatography. After
washing (25 ml of 10 mM Tris/HCl pH 7.0 and 25 ml of 10 mM
Tris/HCl pH 7.0/0.15 M NaCl), recombinant NOV was eluted
with 0.8 M NaCl in 10 mM Tris/HCl (pH 7.0). In a second step,
NOV containing fractions were pooled and further purified on a
HiLoad 16/60 Superdex
TM column with 10 mM Tris/HCl
(pH 7.0) as running buffer.
CCN2/CTGF ELISA
The ELISA for quantification of human CCN2/CTGF was
described before [35]. Briefly, the antibodies (rabbit-anti-human
CCN2/CTGF (sc-25440) for plate coating, goat-anti human
CCN2/CTGF (sc-14939) for detection, and donkey anti-goat IgG-
HRP (sc-2056) for visualisation) were all obtained from Santa
Cruz. The microtiterplates were first coated overnight at 4uC with
a 1:1000 dilution of antibody sc-25440 in coating buffer [50 mM
natrium carbonate (pH 9.6): 1.59 g/l Na2CO3 and 2.93 g/l
NaHCO3]. The plates were then rinsed three times with PBST
(PBS with 0.05% Tween-20) and supernatants were mixed with an
equal volume of PBST and dispensed into the wells and incubated
at RT under shaking for 2 h. The probes removed, wells rinsed
with PBST and the second antibody against CCN2/CTGF (sc-
14939) dispersed in a 1:1000 dilution into every well and incu-
bated for 2 h at RT. After a further washing, the anti-goat IgG-
HRP conjugate was dispersed in a 1:15000 dilution for 1 h. The
plates were washed three times and developed by addition of the
3,39,5,5-tetramethyl benzidine (TMB) substrate at RT for 10 min.
The reaction was stopped in 2 M H2SO4 and the absorbance at
Recombinant CCN2/CTGF and CCN3/NOV
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counter. The concentration was measured in duplicate.
2-D PAGE and mass-spectrometric analysis
Immobilized pH gradient strips (ReadyStrip
TM IPG Strip, pH
range 3–10, #163-2000, Bio-Rad Laboratories, Philadelphia, PA)
were re-hydrated in the PROTEANH IEF focusing tray. The
protein sample was re-suspended in 125 ml of re-hydration buffer
(9 M Urea, 4% CHAPS, 0.4% Ampholyte, 65 mM DTT and
Bromphenol Blue) and applied as a line along the edge of channel
in the PROTEANH IEF focusing tray and covered with the
immobilized pH gradient (IPG) strips (7 cm length). Before
starting the active re-hydration, the IPG strip was passively re-
hydrated for one hour until the liquid was absorbed by the gel bed.
The IPG strips with the re-hydration buffer/protein solution were
covered with mineral oil to prevent the evaporation during active
re-hydration and entrance of the proteins into the gel of the IPG
strip overnight. Wet electrode wicks were inserted between the
IPG strips and the electrodes. The active re-hydration of the
protein species on the IPG strips was done in the PROTEANH
IEF Cell overnight (16 hr): 50 V, 20uC. The focussing program
was performed in the PROTEANH IEF Cell (Bio-Rad). The first
step of focusing was done rapidly linear at 500 V for 250 Vh, the
second step was done from rapidly linear at 1000 V for 500 Vh.
The third step was done rapidly linear at 8000 V for 6500 Vh.
The program ended at constant 500 V.
Before running the second dimension, the IPG strips were
equilibrated in SDS-containing buffers. The first equilibration
buffer containing DTT reduces sulfhydryl groups and the second
equilibration buffer containing iodoacetamide alkylates the
reduced sulfhydryl groups. Briefly, the strips were shortly washed
with Milli-Q water and soaked for 15 min in a buffer containing
6 M Urea, 30% (v/v) glycerol, 2% (w/v) SDS, 0.065 M DTT, and
0.05 M Tris (pH 8.8) on an orbital shaker. Then, the strips were
shortly washed in Milli-Q water and equilibrated for 15 min in a
buffer containing 6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS,
0.135 M iodoacetamide, and 0.05 M Tris (pH 8.8) on the orbital
shaker. The equilibrated IPG strips were placed on the top of the
12% SDS-PAGE that was run in Tris/glycine buffer (248 mM
Tris, 192 mM glycine, 1% (w/v) SDS, pH 8.3) for 20 min at
120 V to force the immobilized protein spots from the strip.
Subsequently, the separation of the protein spots was performed
for 40 min at 180 V. The final gels were analysed by colloid
Coomassie staining, Western blot and in gel digestion was realized
prior to ESI-MS/MS analysis.
ESI/TOF-MS/MS
The identity of CCN3/NOV and CCN2/CTGF was verified
by MS/MS-identification of individual fragments obtained by
tryptic digestion. The polyacrylamide gel was rinsed two times in
Milli-Q water to remove excess SDS from the gel, reducing strong
background during sensitive Coomassie blue staining [36]. Then
the gels were stained overnight in 5% (w/v) aluminium sulphate
hexadecahydrate (06421; FLUKA, Sigma-Aldrich, Munich,
Germany), 10% (v/v) ethanol, 0.02% (w/v) Coomassie Brilliant
Blue (9598.1, CBB-G250, Roth) and 2% (v/v) of 85% o-
phosphoric acid (79620, FLUKA). Thereafter, the gels were
rinsed 2 times in Milli-Q water and bands of interest were excised
with a clean scalpel avoiding background gel volume around of the
Figure 1. Establishing of devices for over-expressing CCN
proteins. (A) Light microscopic images of parental HEK cells (a), Flp-In-
293 (b) and stable transfected WB4 (c) and HEK1/1 (d) clones.
(B) Immunostaining for CCN2/CTGF of stable transfected WB4 (a) and
parental cells (c). Staining with an isotype control (b, d) served as
control. Nuclei were counterstained with propidium iode. (C) CCN2/
CTGF expression in stable transfected clones and parental cells was
tested in Western Blot in cells stimulated with TGF-b1 or untreated cells.
(D) Expression of CCN3/NOV was analysed in extracts and supernatants
of mock- or Ad-CMV-NOV-infected COS-7 cells.
doi:10.1371/journal.pone.0016000.g001
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transferred into a 1.5 ml microcentrifuge tubes. The gel cubes
were washed with 150 ml of Milli-Q water and spinned down with
maximum speed in a table centrifuge. The supernatant was
replaced by 4 volumes of acetonitrile per volume of gel pieces and
the gel pieces were dried for 15 min. After spinning in a
microcentrifuge, the acetonitrile was removed and replaced by
10 mM DTT in 0.1 M NH4HCO3. After incubation (30 min,
37uC) the gel pieces were collected by centrifugation and the
supernatant replaced with acetonitrile for 15 min. The gel pieces
were spinned down again and the supernatant replaced with
55 mM iodoacetamide in 0.1 M (NH4)HCO3 and further
Figure 2. Purification of recombinant CCN proteins. (A) Analysis of purification of recombinant CCN2/CTGF from supernatants of stable
transfected WB4 clone by SDS-PAGE and subsequent Coomassie stain. Bacterially expressed CCN2/CTGF (1 and 2 mg) served as an internal control.
(B) Western blot analysis of individual fractions using a CCN2/CTGF-specific antibody. (C) Analysis of purification of CCN3/NOV from supernatants of
COS-7 that were transiently infected with Ad-CMV-CCN3/NOV in Ponceau S stain. (D) The membrane from (C) was probed with a CCN3/NOV-specific
antibody. (E) Different amounts (20 and 45 mg) of purified CCN3/NOV taken from fraction 2 (C, D) were analysed in Coomassie stain (left panel),
Ponceau S stain (middle panel) and Western blot (right panel) with a CCN3/NOV-specific antibody.
doi:10.1371/journal.pone.0016000.g002
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replaced and gel pieces soaked for 15 min in 200 ml 0.1 M
(NH4)HCO3 to remove traces of iodoacetamide. The supernatant
was removed after spinning and the gel pieces dried in the vacuum
centrifuge. The gel pieces were re-hydrated in digesting buffer
containing 50 mM NH4HCO3, 5 mM CaCl2 and 12.5 ng/ml
trypsin at 4uC for 45 min, and incubated overnight at 37uC. 15 ml
of 25 mM NH4HCO3 was added and gel pieces were centrifuged
for 15 min. Two volumes of acetonitrile were added, and probes
incubated at 37uC for 15 min with shaking, and the supernatants
collected after centrifugation. 50 ml of 5% (v/v) formic acid was
added and the suspension mixed for 15 min at 37uC. The extracts
were pulled down and dried in a vacuum centrifuge. Identification
of peptides was performed using a nanoHPLC (Dionex,
Sunnyvale, CA) coupled to an ESI-MS/MS mass spectrometer
(Micromas electrospray Q-TOF-2, Waters Corporation, Milford,
MA). Protein identification was carried out using the search engine
MASCOT (Matrix Science, Boston, MA).
MALDI-TOF mass spectrometry
Desalting of peptides was done by using the ZipTipCm-C8
devices according to the manufacturer’s instruction (Millipore
Corporation, Billerica, MA). The dried protein samples were
resuspended in 10 ml of 5% (v/v) formic acid in HPLC pure water.
The ZipTipCm-C8 was pre-wetted in 25% (v/v) of mixture of 5%
(v/v) formic acid in HPLC pure water and 75% (v/v) acetonitrile
and equilibrated with 5 volumes of 5% (v/v) formic acid in HPLC
pure water. The proteins were applied on the ZipTipCm-C8 in 10
aspiration and dispensing cycles. Then, the surface of the column
of the ZipTipCm-C18 was washed with 5 volumes of 5% (v/v)
formic acid in HPLC pure water and the proteins were eluted into
a clean vial by dispensing of 2–4 ml of elution solution containing
25% (v/v) of a 5% (v/v) aqueous formic acid solution in HPLC
pure water and 75% (v/v) acetonitrile. The solution was aspirated
and dispensed through the ZipTipCm-C8 at least 10 times.
Subsequently, 1 ml of the eluted protein was dried on the 96-
well MALDI target plate (Gilson, Middleton, USA) and 1 ml of the
Matrix solution containing sinapinic acid in 30–50% of acetoni-
trile, 0.1% trifluoracetic acid and HPLC pure water was pipetted
on the dried protein drop. The mass of recombinant CTGF and
NOV were determined with the MALDI-TOF/TOF mass
spectrometer method (ultrafleXtreme MALDI-TOF/TOF mass
spectrometer, Bruker Daltonics, Bremen, Germany). The protein
standard II (Bruker) that contains three standard proteins
(Trypsinogen, Protein A, Bovine Serum Albumin) with average
m/z 23982, 44613, and ,66500 was used for testing and
calibration of the MALDI mass spectrometer.
Deglycosylation of CCN2/CTGF and CCN3/NOV
The purified CCN proteins were deglycosylated according to
the manufacturer’s instructions (NEB, Ipswich, MA). For degly-
cosylation with the Endo-N-acetyl-b-glucosaminidase H (Endo H),
20 mg of recombinant CCN2/CTGF or CCN3/NOV were mixed
with 1/10
th volume of 106 denaturating buffer (5% (w/v) SDS,
0.4 M DTT) and heated for 10 min at 100uC. Then, the solution
was mixed with 1/10
th volume of the 106reaction buffer (0.5 M
sodium citrate, pH 5.5) and protein deglycosylation was per-
formed with 1000 IU of Endo H for 1 h at 37uC. For deglycosy-
lation with Peptid-N-(N-acetyl-b-glucosaminyl)-asparaginamidase
(PNGase F), 20 mg of each protein was denaturated in 16
denaturation buffer at 100uC for 10 min. Then 1/10
th volume of
each 106G7 reaction buffer (0.5 M sodium phosphate, pH 7.5)
and 10% (v/v) NP-40 was added and deglycosylation was
performed by adding of 1000 IU of PNGase F for 1 h at 37uC.
For glycosylation studies the following antibodies/conjugates were
used: goat-anti-mouse CCN3/NOV (#AF1976, R&D Systems);
goat-anti-human CCN2/CTGF (sc-14939) obtained from Santa
Cruz; rabbit-anti-mouse PDGF type b receptor (#PC17) obtained
from Oncogene (San Diego, CA); Con A-HRP (L6397) obtained
from Sigma-Aldrich (Munich, Germany). Prediction of N-
glycosylation sites was done using the NetNGlyc tool from the
Expert Protein Analysis System (ExPASy) Proteomic Server at
http://expasy.org/.
Biological activity of purified CCN proteins
(i) Cell proliferation. The biological activity of purified
recombinant CCN2/CTGF was tested om EANhy 296 cells.
Therefore, 3610
4 cells were seeded in the wells of a 12-well plate
and cultured overnight in growth medium. The next day, the
medium was changed to starvation medium (0% FCS, 1 mg/ml
BSA) and cells were serum-starved for 16 hr. Thereafter, the
medium was renewed, different amounts of recombinant CCN2/
CTGF (100 ng to 1.5 mg/ml) added, and cells incubated for a
further 24 hr period. Then the medium was replaced against
labeling medium (DMEM, 1 mg/ml BSA, and 0.01 mM 5-
bromo-29-deoxyuridine) and cells incubated for a further 24 hr
Figure 3. Size-exclusion chromatography of purified CCN proteins. (A) Size-exclusion gel chromatography of fraction 2 (cf. Figures 2C and
2D) and subsequent detection of CCN3/NOV in Western Blot. (B) Size-exclusion gel chromatography of bacterial expressed recombinant CCN2/CTGF
(BioVendor) in a buffer containing 10 mM Tris (pH 7.0). (C) Size-exclusion gel chromatography of purified recombinant human CCN2/CTGF in a buffer
containing 10 mM Tris (pH 7.0). (D) Size-exclusion gel chromatography of purified recombinant human CCN2/CTGF in a buffer containing 10 mM Tris
(pH 7.0) and 0.15 M NaCl. As gel filtration standard in (B–D) a mixture of molecular weight markers containing Vitamin B12 (1.35 kDa), horse
Myoglobin (17 kDa), chicken Ovalbumin (44 kDa), bovine c-Globulin (158 kDa), and bovine Thyroglobulin (670 kDa) was applied.
doi:10.1371/journal.pone.0016000.g003
Figure 4. Stability of purified recombinant CCN2/CTGF and
CCN3/NOV. 1 mg of purified CCN2/CTGF and CCN3/NOV that were
kept for three months at indicated temperatures (4uC, 280uC) were
separated on a NuPAGE Bis/Tris 4–12% gradient SDS gel under reducing
and non-reducing conditions and stained with Coomassie. In this
analysis 1 mg of rhCTGF (BioVendor) that was stored at 280uC served as
an internal control.
doi:10.1371/journal.pone.0016000.g004
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1-Step
TM BrdU ELISA (Roche) according to the manufacturer’s
instructions. The absorption was measured in a Wallac Victor 1420
Multilabel counter. (ii) Luciferase assay. EANhy 926 cells were
seeded with 1610
5 cells/well in 6-well plates and incubated
overnight. The next day the medium was renewed and transfected
with 1 mg of the (CAGA)12-MLP-Luc vector using 3 ml of the
TransIT-LT1 transfection reagent (Mirus, VWR International,
Darmstadt, Germany) after another 2-hr incubation time. The next
day, the serum content of the medium was reduced to 0.5% FCS
and cells starved for 16 hr. Thereafter, cells were stimulated in
medium (0.2% FCS) with indicated concentrations of cytokines for
24 hr. Finally, cells were lysed in 16 luciferase lysis buffer
(Promega), LAR substrate added, and the luciferase activity
measured in a Wallac Multilabel counter. The luciferase activity
given in light counts per second was normalized against the protein
concentrationineachsampleandgivenasrelativelightunits(RLU).
Results
Purification of recombinant human CCN2/CTGF and
recombinant rat CCN3/NOV
We cloned expression constructs that direct the expression of
full-length human CCN2/CTGF and rat CCN3/NOV with short
fusions at their carboxyl-terminal regions (Figure S1). For over-
expression of human CCN2/CTGF, we established stable
transfected HEK293A (HEK 1/1, HEK2/2) and Flp-In-293 cell
clones (WB4) that show a strong expression of respective protein
(Figure 1A–1C) that is observable even after 100 cell passages
(Figure S2). In addition, we established an adenoviral expression
vector that directs high expression of rat CCN3/NOV (Figure 1D).
Based on their property to bind heparin, we purified respective
CCN proteins by use of affinity chromatography (Figure 2).
Protein quantification was done with a standard protein quantifi-
cation assay and specific measurement using in-house-CCN2/
CTGF [35] and in-house CCN3/NOV ELISAs (Borkham-
Kamphorst and Weiskirchen, unpublished) as well as Western
blotting. In addition, the purity of respective recombinant CCN
proteins was analysed by applying 1 mg of recombinant proteins to
4–12% Bis/Tris SDS-PAGE electrophoresis following Coomassie
stain. In this analysis, recombinant human CCN2/CTGF typically
appeared as two distinct bands in the range of 38–40 kDa, while
rat CCN3/NOV appeared as one broad smeary band with a
molecular weight of ,48 kDa. When necessary, we further
purified the proteins by Sepharose size-exclusion chromatography
(Figure 3). Interestingly, the buffer salt content showed a strong
influence on the elution profile of recombinant CCN proteins.
Affinity purified CCN3/NOV was fractioned with a bipartite
chromatogram when the gel filtration was run in a buffer that
simply contained 10 mM Tris (Figure 3A). While commercially
available CCN2/CTGF that was expressed in bacteria showed a
tripartite elution profile (Figure 3B), the protein that we have
purified from cell supernatants showed a distinct peak at very low
molecular weight (Figure 3C). However, when the same protein
was run in the same buffer with addition of 150 mM NaCl, we
found that the peak was shifted to a range at which high molecular
weight proteins were eluted (Figure 3D).
We next tested the stability of purified recombinant CCN3/
NOV and CCN2/CTGF. Therefore, we analysed respective
protein solutions that were stored at 4uC and 280uC for up to three
months by SDS-PAGE and Coomassie stain under reducing and
non-reducing conditions (Figure 4). This analysis revealed that both
proteins were rather stable and showed no significant degradation
after storage. When determined the total mass of purified human
CCN2/CTGF and rat CCN3/NOV by MALDI-TOF, we
observed average m/z values (CCN2/CTGF, 38269 Da; CCN3/
NOV, 44993 Da) that were roughly in the range of our expectation
(Figure 5). However, compared to our calibration proteins
(Trypsinogen, Protein A, Albumin) that produced narrow peaks
(Figure 5A), the recombinant proteins produced broad peaks
(Figure 5B, and 5C) in this analysis that were not really appropriate
to determine the mass. To characterise this phenomenon in more
detail, we next performed 2D-gelelectrophoresis in which the
proteins were separated on IPG strips according to their isoelectric
points (1D) and subsequently by their size using 10% SDS-PAGE
(2D). Again, the recombinant proteins produced smears in these 2D
gels (Figure 6) that were completely immunoreactive to specific
antibodies suggesting that the complete smears resulted from
different biochemical subspecies. We isolated spots/bands from 1D-
(CCN2/CTGF) or 2D-gels (CCN3/NOV), subjected them to
trypsin in-gel digesting and identified resulting peptides by ESI-
TOF/MS and subsequent analysis using the MASCOT search
engine (e.g. Table S1 and Table S2) for rapid protein identification
using mass spectrometry data [37]. In this analysis, the sequence
coverage was 34% for human CCN2/CTGF and 26% for rat
CCN3/NOV.
Subsequently, we demonstrated the biological activity of the
purified proteins. The biological activity of recombinant CCN2/
CTGF was proven by stimulation of endothelial cell line EANhy
926 that represents a human intraspecies hybrid [33] that was
previously tested to be highly sensitive against CCN2/CTGF [34].
When cells were stimulated for 24 h with different concentrations
of purified CCN2/CTGF (100–2000 ng/ml) in serum-free
medium, we observed a dosis-dependent increase of proliferation,
while bacterial expressed CCN2/CTGF (bCTGF) that is com-
mercially showed no stimulatory activity in this proliferation assay
(Figure 7). Recombinant CCN2/CTGF induced a 1.6 fold BrdU
incorporation compared to unstimulated controls. PDGF-BB
(25 ng/ml) and TGF-b1 (1 ng/ml) that were incorporated in this
assay as positive and negative controls induced a 2.9-fold induction
or a 50% suppression of BrdU incorporation. Purified rat CCN3/
NOV showed no effect on the BrdU incorporation in this assay
(data not shown).
To analyse if CCN2/CTGF interferes with TGF-b signalling,
we performed reporter gene assays in with EANhy 926 cells using a
reporter containing Smad3/Smad4 binding sequences, termed
CAGA boxes, that were originally derived from the promoter of
the human PAI-1 gene and is a read-out-system for phosphory-
lated Smad3 [32]. We transfected EANhy 926 cells with the
reporter (CAGA)12-MLP-Luc vector and stimulated the cells in
serum-free DMEM for 24 hr with different concentrations/
combinations of recombinant CCN2/CTGF, CCN3/NOV,
TGF-b1, PDGF, bCTGF, and an antagonizing antibody (L-20)
directed against CCN2/CTGF (Figure 8). The obtained luciferase
activities were normalised to the protein amount and calculated as
light count per second per mg protein (lcps/mg protein) and relative
luciferase units (RLU) were compared to un-stimulated controls
that were set to 1. In this assay, TGF-b1 (1 ng/ml) stimulation
Figure 5. MALDI-TOF analysis of purified recombinant CCN proteins. (A) Calibration spectrum of MALDI-TOF mass spectroscopy using a
mixture of proteins that contains Trypsinogen, Protein A, and Albumin with average m/z 23982, 44613, and ,66500 as standards. (B) Mass spectrum
of purified recombinant CCN2/CTGF. (C) Mass spectrum of purified recombinant CCN3/NOV.
doi:10.1371/journal.pone.0016000.g005
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PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e16000Figure 6. 2D-SDS-PAGE, trypsin in-gel digest, ESI-TOF/MS and sequence identification of protein spots from recombinant CCN3/
NOV. (A) 2D-SDS-PAGE of purified recombinant CCN3/NOV. The protein was first separated in its native state by isoelectric focussing in a pH gradient
rangingfrom3 to10andlaterbytheirproteinmassinadenaturingSDS-PAGE.ThefinalgelwasstainedwithCoomassieBrilliantBlue.(B)Indicatedspots
(spot 1 to 10) were subjected to trypsin in gel digest. (C) A parallel gel of (A) was prepared and transferred without prior Coomassie stain to a Protran
membrane. The membrane was stained with Ponceau S. (D) The membrane (C) was then probed with a CCN3/NOV-specific antibody.
doi:10.1371/journal.pone.0016000.g006
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stimulation decreases luciferase activity to 0.18 of the unstimulated
control. Stimulation with 2 mg/ml of purified CCN2/CTGF
induced the luciferase activity by a factor of 10, while the
stimulation with 1 mg/ml of purified NOV decreased the luciferase
activity to 0.6 fold. In the presence of the capturing antibody, the
stimulatory effect of CCN2/CTGF on luciferase activity was
negotiated. In line, the capturing antibody itself decreases
luciferase activity to 0.4-fold of unstimulated control suggesting
that the biological activity of endogenous expression of CCN2/
CTGF in EANhy 926 cells (Figure S3) is blocked by sequestering.
There was no increase of luciferase activity observable in the
bCTGF-stimulated and transiently transfected EANhy 926 cells.
We could show a significant difference between stimulated
(500 ng/ml, 1000 ng/ml) and unstimulated EANhy 926 cells
(p#0.05) using double-sided t-test (Figure S4).
We next tested the effect of the purified proteins on biochemical
cell activity. Therefore, equal cell numbers of EANhy 926 cells were
seeded, serum-starved overnight and stimulated with TGF-b1,
PDGF-BB, recombinant human CCN2/CTGF and rat CCN3/
Figure 7. Biological activity of purified recombinant CCN2/CTGF, part I. (A)E A Nhy 926 cells in serum-free growth medium were incubated
with indicated concentrations of bacterial expressed recombinant CCN2/CTGF (BioVendor) and subjected to BrdU incorporation assay. (B)E A Nhy 926
cells in serum-free growth medium were subjected to indicated concentration of purified recombinant CCN2/CTGF and analysed in BrdU
incorporation assay. The observed proliferation rates were set in relation to control cells that received no recombinant CCN2/CTGF. (C)E A Nhy 926 cells
in serum-free growth medium were left untreated or stimulated with TGF-b1 (1 ng/ml) and PDGF-BB (25 ng/ml) and the proliferation was measured
in BrdU assay. (D)E A Nhy 926 cells were transiently transfected with the (CAGA)12-Luc reporter plasmid and incubated with TGF-b1 (10 ng/ml),
indicated concentrations of recombinant CCN2/CTGF or left unstimulated. The relative luciferase activity was measured after 24 hr. The gene
promoter activity of the unstimulated control cells was set to 1 in this experiment.
doi:10.1371/journal.pone.0016000.g007
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PLoS ONE | www.plosone.org 11 December 2010 | Volume 5 | Issue 12 | e16000Figure 8. Biological activity of purified recombinant CTGF, part II. (A)E A Nhy 926 cells were transfected withthe (CAGA)12-Luc reporter plasmid
and incubated with indicated concentrations of recombinant human CCN2/CTGF. Cell lysates were prepared after 24 hr and luciferase activity determined.
Inthis assay,theluciferase activityofnormal control cells (0 ng/ml) was set to 1.Theexperiments were repeated three times. Shown are the means 6SDof
one representative experiment performed in triplicate. (B)E A Nhy 926 cells were transfected with the reporter plasmid and incubated with different
concentrationsof CCN3/NOV (500 or 1000 ng/ml) or PDGF (50 ng/ml) in serum-free medium. Thepromoter activityofthe unstimulated controls was set as
1. The experimentwas done three times in triplicate. The diagram depictsthe means 6SD of one representative experiment. (C)Aftertransfectionwith the
Smad3 sensitivereporter, EANhy926 cellswereincubatedwith recombinant CCN3/CTGF, acombinationofCCN2/CTGF andCCN2/CTGF-specific antibody L-
20, L-20 alone, or left untreated. 24 hrlater, therelative luciferaseactivitywas determined. The experiment was repeated three times. Shown are ther e s u l t s
(means 6SD) of one representative experiment that was performed in triplicate. (D–G)E A Nhy 926 cells were transiently transfected with the (CAGA)12-Luc
reporter plasmid and incubated with indicated concentrations/combinations of PDGF-BB, TGF-b1, CCN2/CTGF, CCN2/CTGF capturing antibody (L-20, sc-
14939), and bacterial expressed CCN2/CTGF in serum-free medium. The promoter activity was measured 24 hr later.
doi:10.1371/journal.pone.0016000.g008
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and whole cell lysates for comparative quantification (the amount
of proteins in unstimulated cells were set to 1) of total protein
concentration prepared. We found that cells treated with PDGF-
BB had a 1.6-fold higher protein amount than unstimulated
controls. In EANhy 926 cells that were stimulated with CCN3/
NOV (500 ng/ml), the protein amount was decreased to 0.6-fold
of the unstimulated control. Likewise, stimulation with 1 ng/ml of
Figure 9. Glycosylation of CCN proteins. (A–D) Purified fraction of CCN3/NOV (A, B) or CCN2/CTGF (C, D) that were stored at indicated
temperatures for three months were subjected to denaturing (+ DTT) and non-denaturing (2 DTT) SDS-PAGE (Bis/Tris 4–12% gradient). The gels were
blotted onto Protran membranes and subsequently probed with a CCN3/NOV- (A), a CCN2/CTGF- (C), or a ConA-HRP conjugate (B, D). In this
analysis, a soluble PDGF type b receptor (PDGFRb) was used as a highly glycosylated protein control. BSA and the bacterial expressed CCN3/CTGF
(BioVendor) were used as negative controls. In this set of experiments the blots A and C were cut at indicated cut edges prior incubation with
antibodies directed against CCN proteins or PDGFRb.
doi:10.1371/journal.pone.0016000.g009
Figure 10. Deglycosylation of CCN proteins. (A)1mg of recombinant CCN3/NOV or CCN2/CTGF was subjected to deglycosylation assay using
the endoglycosidase Endo H (removes only high mannose and some hybrid types of N-linked carbohydrates) and PNGase F (removes carbohydrates
attached to an Asn). The digested proteins were then resolved by SDS-PAGE (NuPAGE Bis/Tris 4–12% gradient) and probed with indicated antibodies.
doi:10.1371/journal.pone.0016000.g010
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unstimulated control. CCN2/CTGF had no influence on the
protein amount (Figure 9).
Based on the finding that the purified CCN proteins appeared not
as unique populations in gel electrophoresis (cf. Figure 6) and showed
atypical chromatography behaviour (cf. Figure 3), we analysed if the
heterogeneity resulted from glycosylation. When we analysed the
human CCN2/CTGF and rat CCN3/NOV protein sequences for
potential N-glycosylation sites using the NetNGlyc algorithm (http://
www.cbs.dtu.dk/services/NetNGlyc/), we found that both proteins
carry a potential N-glycosylation site (Figure S5). To test if the
proteins are indeed N-glycosylated, we first analysed if the respective
proteins have lectin binding capacity using a Con A-HRP conjugate
(Figure 10). As negative and positive controls, 1 mgB S Aa n dt h e
soluble highly glycosylated extracellular part of the PDGF-BB
receptor [38] was incorporated into this assay. Additionally, bacterial
expressed recombinant CTGF (bCTGF) that should contain no
sugar groups was analysed in parallel. In this analysis, we found that
both recombinant proteins from eukaryotic sources and the
extracellular domain from the PDGF type b receptor (PDGFRb)
were detectable with the Concanavalin (ConA)-HRP conjugate
suggesting that these proteins carrysugar groups. In contrast, CCN2/
CTGF that originated from a bacterial source was only detected by
the L-20 antibody but not by Con A. In a second set of experiments,
we tried if the purified CCN proteins could be enzymatically
deglycosylated by Endo H (removes only high mannose and some
hybrid types of N-linked carbohydrates) or PNGase F (removes all
types of N-linked carbohydrates). This analysis revealed that
incubation of CTGF with one of both enzymes was suitable to
remove the affinity for the Con A-HRP conjugate, while the
respective affinity of CCN3/NOV was only removed after treatment
withPNGaseF(Figure11).Inaddition,thetreatmentwithPNGaseF
resulted in a marked alteration of electrophoretic mobility.
A previous study reports that CCN2/CTGF and CCN3/NOV
can regulate their expression in an Yin/Yang manner and that
either the addition or over-expression of CCN3/NOV produces a
marked down-regulation of CCN2/CTGF in mesangial cells [25].
To test if this effect is also reproducible in EANhy 926 cells, equal
cell numbers were seeded, serum-starved overnight, and cultured
in conditioned medium enriched in recombinant human CCN2/
CTGF. Thereafter, the cells were washed, whole cell lysates
prepared and analysed for CCN3/NOV expression revealing that
EANhy 926 cells, that normally express both CCN proteins,
produce less amounts of endogenous CCN3/NOV after CCN2/
CTGF treatment (Figure 12).
Discussion
Protein studies aiming to unravel biological functions require
pure and native proteins that might be further dependent on their
Figure 11. Measurement of mitogenic activity of different growth factors. EANhy 926 cells were incubated with different concentrations of
growth factors in serum-free medium. Protein amounts of whole cell lysates were measured by Micro BCA assay after 48 hr. In this analysis, the
protein amount in untreated cells was set to 1. The experiments were repeated three times. Shown are the means 6 SD of one representative
experiment that was performed in triplicate.
doi:10.1371/journal.pone.0016000.g011
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correct configuration of carbohydrate chains is important in the
signalling of growth factors [39].
In this study, we have established novel devices for expression of
recombinant human CCN2/CTGF and rat CCN3/NOV
(Figure 1). By use of heparin affinity and size exclusion
chromatography, we were able to purify both CCN proteins to
heterogeneity (Figure 2). Typically, these expression devices allow
to purify 200–300 mg of recombinant human CCN2/CTGF from
400 ml growth medium of stable transfected Flp-In-293 clones and
approximately 300 mg recombinant rat CCN3/NOV from 400 ml
conditioned supernatant of COS-7 cells that were infected with
Ad5-CMV-rNOV. The identity of purified proteins was demon-
strated by mass spectrometry (Figure 5) and trypsin in-gel-digest
(Figure 6) following identification of resulting peptides by ESI-
MS/MS and subsequent analysis using the MASCOT algorithm.
We further demonstrate that the purified proteins are highly
stable when stored at 280uCo r4 uC (Figure 4). Interestingly, the
retention time of purified CTGF in size exclusion chromatography
was strongly dependent on the salt content of chosen buffer. Low
salt concentration prolonged the retention time, while higher salt
concentrations (150 mM) leads to shorter retention times (Figure 3).
Although this phenomenon is known for many other proteins, the
drastic shift of the elution time might indicate that CCN2/CTGF
strongly interacts with the sepharose matrix representing a
crosslinked, beaded-form of a polysaccharide polymer material
(agarose) that is crosslinked through lysine side chains.
The biological activity of the isolated proteins is the key
indicator of successful expression. For recombinant CCN2/CTGF
we have shown the biological activity by use of its positive
influence on proliferation in EANhy 926 cells [34] and in a reporter
gene assays using the Smad3/4-sensitve reporter (i.e. (CAGA)12-
MLP-Luc)) that originally originated from the human PAI-1 gene
promoter [32]. After addition of CCN2/CTGF, we found an
increase of proliferation in BrdU incorporation assay of around
150% (Figure 7), values that were similar to those observed in
pancreatic stellate cells [40]. In this assay, the EANhy 926 cells were
also increased after stimulation with PDGF-BB and decreased
after TGF-b1 stimulation and moreover bacterial expressed
CCN2/CTGF failed to influence proliferation of EANhy 926 cells.
The results obtained after transient transfection of EANhy 926 cells
with the reporter vector (CAGA)12-MLP-Luc showed an increase
of the firefly luciferase read that was dose-dependent and blocked
by the addition of an antagonistic antibody (Figure 8). Even more,
this antibody was suitable to block the stimulatory effect of
endogenous CCN2/CTGF. Contrarily, the stimulation with
recombinant NOV leads to a 0.6-fold decrease in luciferase
activity suggesting that NOV might evolve opposing activities
towards CCN2/CTGF. That finding fits well with the recent
hypothesis that the expression of CCN2/CTGF and CCN3/NOV
is controlled in an Yin/Yang manner [25] and was further
highlighted by the fact that the expression of CCN3/NOV in
EANhy 926 cells could be decreased by supplementation of growth
medium with CTGF (Figure 12).
Figure 12. Yin and Yang regulation of CCN3/NOV and CCN2/CTGF. (A) Supernatants (S) or protein cell extracts (L)o fE A Nhy 926 cells or
parental HEK cells that were incubated under indicated conditions (24 hr) were analysed for expression of CCN3/NOV and CCN2/CTGF in Western
blot. (B)E A Nhy 926 cells were cultured in the presence of conditioned media taken from Flp-In-293 clones over-expressing CCN2/CTGF. Cell lysates (L)
or supernatants (S) were then tested for expression of CCN3/NOV and CCN2/CTGF by Western blot. Shown are representatives of two independent
experiments.
doi:10.1371/journal.pone.0016000.g012
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that both purified recombinant CCN proteins are N-glycosylated
(Figures 10 and 11). Both proteins (i) have affinity for the Con
A-HRP conjugate that is lost after treatment with endoglycosi-
dases, (ii) migrate as diffuse bands in SDS-PAGE, and (iii) appear
not uniform in mass spectrometry. We could demonstrate a
prominent shift in molecular weight after deglycosylation with
PNGase F for CCN3/NOV in SDS gel electrophoresis that is
associated with a reduced lectin binding activity. Likewise CCN2/
CTGF that originated from eukaryotic sources had affinity for the
Con A-conjugate that was not found in CCN2/CTGF that was
expressed in bacteria and lost after treatment with either PNGase
F or Endo H (Figure 11). Prediction that have been done on the
ExPASy Proteomics Server show two N-glycosylation sites at
positions 28 NCSG (high potential) and 225 NASC (low potential)
in human CCN2/CTGF and at positions 91 NETG (potential)
and 274 NCTS (low potential) in rat NOV. There were no
predictions for O-glycosylation sites in human CCN2/CTGF and
only one predicted O-glycosylation site at threonine 43. The
activity of growth factors and signalling proteins are depended on
the post-translational modifications including glycosylation and
correct building of the intramolecular disulfide bond network.
These modifications are difficult to perform in E. coli expressing
system [41] but obviously accurately done in our eukaryotic
expression systems (i.e. HEK, COS-7). Although we do not yet
know if N-glycosylation is a post-translational modification that is
important for the folding or biological activity of these CCN
proteins, it might be an essential prerequisite for proper protein
secretion and adhesion/incorporation into the ECM or to prevent
premature degradation.
Incubation of EANhy 926 cells with conditioned medium isolated
from WB4 over-expressing human CCN2/CTGF resulted in an
increase of endogenous CTGF and suppression of endogenous
CCN3/NOV. This data confirms previous suggestions that
exogenous CCN2/CTGF is able to suppress expression of
CCN3/NOV in a Yin/Yang manner [25].
In summary, we have established an expression and purification
system to manufacture biological active recombinant human
CCN2/CTGF and rat CCN3/NOV in permanent mammalian
cell lines. Both CCN proteins are rather stable and can be stored
at 4uCo r280uC for at least 3 month without disintegration. The
biological activity of both proteins was demonstrated in gene
reporter and proliferation assays.
The opportunity to prepare large quantities of biological active
CCN2/CTGF and CCN3/NOV proteins will now allow us to
address key questions of these CCN proteins in regard to structure,
function, post-translational modifications (e. g. glycosylation),
involvement in individual signal cascades, and further provide a
foundation to address their therapeutic potential in various disease
models.
Supporting Information
Figure S1 Recombinant CCN proteins expressed in this
study. (A, B) Sequence of modified human CCN2/CTGF (A) and
rat CCN3/NOV (B) expressed in this study. The predicted leader
sequences are depicted in blue and the amino acid introduced by
the chosen cloning strategy in red. The numbers of amino acid
positions are depicted on the left margin. Potential cleavage sites are
marked by arrows. In addition the theoretical isoelectric points (pI)
and molecular weights (Mw) of expressed proteins, endogenous
proteins, and expressed fusion proteins after removal of leader
sequence are given in red, black and blue, respectively.
(TIF)
Figure S2 CCN2/CTGF expression in selected clones
after prolonged passages. The expression of CCN2/CTGF in
cell extracts (L) and supernatants (S) of indicated clones that were
cultured in medium containing different amounts of FCS was
analyzed by Western blot. In this analysis purified recombinant
CCN2/CTGF was used as a positive control.
(TIF)
Figure S3 Analysis of CCN2/CTGF expression in dif-
ferent cell lines that were used in this study. A Western
blot analysis was performed to analyze CCN2/CTGF expression
in cell extracts of indicated cell lines that were cultured in medium
containing different amounts of FCS. Purified recombinant
CCN2/CTGF was used as a positive control.
(TIF)
Figure S4 Statistical analysis of reporter gene assays.
The graph depicts the results of a two-sided t-test of three
individual (CAGA)12-MLP-Luc reporter gene assays in which
EANhy 926 cells were stimulated with indicated proteins/cytokines.
(TIF)
Figure S5 Potential N-glycosylation sites. A NetNGlyc-
analysis was performed with (A) human CCN2/CTGF and (B) rat
CCN3/NOV. Both proteins contain two potential N-glycosylation
sites at indicated positions.
(TIF)
Table S1 Identification of fragments by ESI-TOF/MS
for human CCN2/CTGF.
(DOC)
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